Precision Medicine

With breast cancer rates rising among young women, a gamified digital health app is empowering patients to overcome medical age bias and demand early care.

A new partnership between Neumarker and Cortica aims to end the trial-and-error approach in autism care by using AI to analyze complex brain wave data.

Elephas Biosciences' live-tissue platform achieves 93% accuracy in predicting immunotherapy response, paving a lucrative path for functional precision oncology.

Transcripta Bio and Mayo Clinic are combining artificial intelligence and living patient data to map ALS, highlighting how institutions fuel precision medicine.

A $29 million gift to Sunnybrook Health Sciences Centre accelerates Canada's precision oncology race while highlighting a reliance on private wealth.

Modern medicine’s greatest triumphs in oncology and rheumatology are inadvertently fueling a silent surge in Secondary Immunodeficiencies.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

As new clinical data debuts at CNS 2026, the intersection of advanced multi-omic tools and state Medicaid policy signals a new era for pediatric care.

As iMDx prepares for the BTIG Kidney Health Forum, the diagnostics challenger is leveraging European clinical data to disrupt the post-transplant testing market.

A new three-tier triage framework aims to protect prostate cancer patients from the lethal cardiovascular risks of life-extending hormone therapies.

Oncodesign Precision Medicine is advancing its LRRK2 inhibitor OPM-201 toward Phase 1b. Here is how strategic repatriation and non-dilutive funding are paving the commercial pathway.

Survival rates for childhood cancer have soared from 25% in the 1960s to 87% today, fueled by precision medicine. Yet, a severe global equity gap persists.

As the Progeria Research Foundation honors pioneer David R. Liu and philanthropists Cathy and Dave Gravel, the ultimate biological network upgrade approaches clinical reality.

A newly expanded partnership between ALZpath and Quanterix signals a massive shift in neurology, replacing costly PET scans with scalable blood-based biomarkers.

As the BCI race intensifies, Europe’s MINIGRAPH consortium unveils a magnetically guided, graphene-based implant that navigates curved brain pathways.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

As commercial sperm banks expand genetic testing to include adult-onset cancer risks, prospective parents face a new frontier of complex, life-altering data.

By mandating hereditary cancer testing for all new sperm donors, Xytex is pushing the fertility industry into complex ethical and legal territory.

Dr. Judy Benjamin walked 550 miles to share her Alzheimer's recovery. But her inspiring journey also highlights the booming business of cognitive optimization.

A new peer-reviewed study validates RenovoRx's targeted catheter platform, offering a strategic bridge as the company approaches its 2027 Phase III readout.